Should Pneumococcal Serotype 3 Be Included in Serotype-Specific Immunoassays?
Since the introduction of the 13-valent pneumococcal conjugate vaccine, a number of studies have demonstrated the limited efficacy of the pneumococcal serotype 3 component of this vaccine. Evidence from seven countries (Denmark, France, Greece, Portugal, Sweden, UK, US) shows limited or no effective...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-01-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2076-393X/7/1/4 |